Improvement in coronary heart disease risk factors during an intermittent fasting/calorie restriction regimen: Relationship to adipokine modulations

Nutrition & Metabolism

Krista A Varady²  Christine C Tangney¹  John F Trepanowski²  Surabhi Bhutani²  Monica C Klempel²  Cynthia M Kroeger² 

[1] Department of Clinical Nutrition, Rush University, Chicago, IL, USA;Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA

关键词: Obese women;    Coronary heart disease;    Cholesterol;    Visceral fat;    Body weight;    Liquid diet;    Calorie restriction;    Intermittent fasting;   

Others  :  811807
DOI  :  10.1186/1743-7075-9-98

 received in 2012-08-13, accepted in 2012-10-05,  发布年份 2012

【 摘 要 】

Background

The ability of an intermittent fasting (IF)-calorie restriction (CR) regimen (with or without liquid meals) to modulate adipokines in a way that is protective against coronary heart disease (CHD) has yet to be tested.

Objective

Accordingly, we examined the effects of an IFCR diet on adipokine profile, body composition, and markers of CHD risk in obese women.

Methods

Subjects (n = 54) were randomized to either the IFCR-liquid (IFCR-L) or IFCR-food based (IFCR-F) diet for 10 weeks.

Results

Greater decreases in body weight and waist circumference were noted in the IFCR-L group (4 ± 1 kg; 6 ± 1 cm) versus the IFCR-F group (3 ± 1 kg; 4 ± 1 cm). Similar reductions (P < 0.0001) in fat mass were demonstrated in the IFCR-L (3 ± 1 kg) and IFCR-F group (2 ± 1 kg). Reductions in total and LDL cholesterol levels were greater (P = 0.04) in the IFCR-L (19 ± 10%; 20 ± 9%, respectively) versus the IFCR-F group (8 ± 3%; 7 ± 4%, respectively). LDL peak particle size increased (P < 0.01) in the IFCR-L group only. The proportion of small LDL particles decreased (P < 0.01) in both groups. Adipokines, such as leptin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and insulin-like growth factor-1 (IGF-1) decreased (P < 0.05), in the IFCR-L group only.

Conclusion

These findings suggest that IFCR with a liquid diet favorably modulates visceral fat and adipokines in a way that may confer protection against CHD.

【 授权许可】

   
2012 Kroeger et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Mattson MP, Wan R: Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. J Nutr Biochem 2005, 16(3):129-137.
• [2]Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, et al.: The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) 2011, 35(5):714-727.
• [3]Williams KV, Mullen ML, Kelley DE, Wing RR: The effect of short periods of caloric restriction on weight loss and glycemic control in type 2 diabetes. Diabetes Care 1998, 21(1):2-8.
• [4]Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI: Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord 2003, 27(5):537-549.
• [5]Tsai AG, Wadden TA: The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006, 14(8):1283-1293.
• [6]Northcott JM, Yeganeh A, Taylor CG, Zahradka P, Wigle JT: Adipokines and the cardiovascular system: mechanisms mediating health and disease. Can J Physiol Pharmacol 2012, 90(8):1029-1059.
• [7]Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ: Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001, 108(10):1533-1540.
• [8]Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, et al.: Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 2002, 40(5):748-754.
• [9]Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V: C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 2006, 95(3):511-518.
• [10]Madjid M, Willerson JT: Inflammatory markers in coronary heart disease. Br Med Bull 2011, 100:23-38.
• [11]Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I: Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008, 49(5):1015-1023.
• [12]Basarici I, Altekin RE, Demir I, Yilmaz H: Associations of isoprostanes-related oxidative stress with surrogate subclinical indices and angiographic measures of atherosclerosis. Coron Artery Dis 2007, 18(8):615-620.
• [13]Shanahan CM, Weissberg PL: Smooth muscle cell phenotypes in atherosclerotic lesions. Curr Opin Lipidol 1999, 10(6):507-513.
• [14]Matsuzawa Y, Funahashi T, Nakamura T: The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011, 18(8):629-639.
• [15]Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S: Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56(4):1010-1013.
• [16]Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO: A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr 1990, 51(2):241-247.
• [17]Hoefner DM, Hodel SD, O'Brien JF, Branum EL, Sun D, Meissner I, et al.: Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001, 47(2):266-274.
• [18]Poynten AM, Markovic TP, Maclean EL, Furler SM, Freund J, Chisholm DJ, et al.: Fat oxidation, body composition and insulin sensitivity in diabetic and normoglycaemic obese adults 5 years after weight loss. Int J Obes Relat Metab Disord 2003, 27(10):1212-1218.
• [19]Kudchodkar BJ, Sodhi HS, Mason DT, Borhani NO: Effects of acute caloric restriction on cholesterol metabolism in man. Am J Clin Nutr 1977, 30(7):1135-1146.
• [20]Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G: Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 2007, 13(21):2169-2175.
• [21]Klempel MC, Varady KA: Reliability of leptin, but not adiponectin, as a biomarker for diet-induced weight loss in humans. Nutr Rev 2011, 69(3):145-154.
• [22]Masquio DC, de Piano A, Sanches PL, Corgosinho FC, Campos RM, Carnier J, et al.: The effect of weight loss magnitude on pro/anti-inflammatory adipokines and carotid intima-media thickness in obese adolescents engaged in interdisciplinary weight-loss therapy. Clin Endocrinol (Oxf) 2012,  : .
• [23]Reidy SP, Weber J: Leptin: an essential regulator of lipid metabolism. Comp Biochem Physiol A Mol Integr Physiol 2000, 125(3):285-298.
• [24]Feingold KR, Adi S, Staprans I, Moser AH, Neese R, Verdier JA, et al.: Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. Am J Physiol 1990, 259(2 Pt 1):E177-E184.